The replicability of oncolytic virus: Defining conditions in tumor virotherapy
Pages: 841  860,
Volume 8,
Issue 3,
July
2011
doi:10.3934/mbe.2011.8.841 Abstract
References
Full text (361.5K)
Related Articles
Jianjun Paul Tian  Mathematics Department, College of William and Mary, Williamsburg, VA 23187, United States (email)
1 
M. Aghi and R. L. Martuza, Oncolytic viral therapythe clinical experience, Oncogene, 24 (2005), 78027816. 

2 
Z. Bajzer, T. Carr, K. Josic, S. J. Russel and D. Dingli, Modeling of cancer virotherapy with recombinant measles viruses, J. Theoretical Biology, 252 (2008), 109122. 

3 
J. Carr, "Applications of Centre Manifold Theory," Applied Mathematics Sciences, 35, SpringerVerlag, New YorkBerlin, 1981. 

4 
E. A. Chiocca, Oncolytic viruses, Nature Reviews, Cancer, 2 (2002), 938950. 

5 
D. Dingli, M. D. Cascino, K. JosiÄ‡, S. J. Russell and Z. Bajzer, Mathematical modeling of cancer radiovirotherapy, Math. Biosci., 199 (2006), 5578. 

6 
A. Friedman, J. P. Tian, G. Fulci, E. A. Chiocca and J. Wang, Glioma virotherapy: Effects of innate immune suppression and increased viral replication capacity, Cancer Research, 66 (2006), 23142319. 

7 
B. A. Fuchs and V. I. Levin, "Functions of A Complex Variable," Pergamon Press, London, 1961. 

8 
G. Fulci, et al, Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses, PNAS Proceedings of the National Academy of Sciences of the United States of America, 103 (2006), 1287312878. 

9 
B. D. Hassard, N. D. Hazzarinoff and Y.H. Wan, "Theory and Applications of Hopf Bifurcation," Cambridge, 1981. 

10 
H. Kambara, H. Okano, E. A. Chiocca and Y. Saeki, An oncolytic HSV1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor, Cancer Res., 65 (2005), 28322839. 

11 
A. S. Novozhilov, F. S. Berezovskaya, E. V. Koonin and G. P. Karev, Mathematical modeling of tumor therapy with oncolytic viruses: Regimes with complete tumor elimination within the framework of deterministic models, Biology Direct, 1 (2006), 118. 

12 
Y. Tao and Q. Guo, The competitive dynamics between tumor cells, a replicationcompetent virus and an immune response, J. Math. Biol., 51 (2005), 3774. 

13 
D. Vasiliu and J. P. Tian, Periodic solutions of a model for tumor virotherapy, Discrete and Continuous Dynamical Systems Ser. S, 4 (2011), 15871597. 

14 
L. M. Wein, J. T. Wu and D. H. Kirn, Validation and analysis of a mathematical model of a replicationcompetent oncolytic virus for cancer treatment: Implications for virus design and delivery, Cancer Res., 63 (2003), 13171324. 

15 
D. Wodarz, Viruses as antitumor weapons: Defining conditions for tumor remission, Cancer Res., 61 (2001), 35013507. 

16 
D. Wodarz and N. Komarova, Towards predictive computational models of oncolytic virus therapy: Basis for experimental validation and model selection, PloS ONE, 4 (2009), e4271. 

17 
D. Wodarz, Gene therapy for killing p53negative cancer cells: Use of replicating versus nonreplicating agents, Hum. Gene Ther., 14 (2003), 153159. 

18 
J. T. Wu, H. M. Byrne, D. H. Kirn and L. M. Wein, Modeling and analysis of a virus that replicates selectively in tumor cells, Bull. Math. Biol., 63 (2001), 731768. 

Go to top
